Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Amelia B. Zelnak"'
Autor:
Shravan Kandula, Jeffrey M. Switchenko, Saul Harari, Carolina Fasola, Donna Mister, David S. Yu, Amelia B. Zelnak, Mylin A. Torres
Publikováno v:
International Journal of Breast Cancer, Vol 2015 (2015)
Among breast cancer patients treated with neoadjuvant chemotherapy (NAC) and mastectomy, locoregional recurrence (LRR) rates are unclear in women with ER+ tumors treated with adjuvant endocrine therapy without postmastectomy radiation (PMRT). To dete
Externí odkaz:
https://doaj.org/article/3c59f659c91c4c4d94ded16d72437353
Autor:
Amelia B. Zelnak, Heinz-Josef Lenz, Kerry Culm, Lukas Makris, Valerie Chamberlain Santos, Hagop Youssoufian, Colleen Mockbee, Kathy D. Miller
Publikováno v:
Cancer Research. 83:OT2-16
Objective: The objective of this Phase 2, open-label, multicenter study is to investigate the antitumor activity of navicixizumab monotherapy or in combination with chemotherapy in patients with advanced solid tumors. Cohort C will enroll triple-nega
Autor:
Kevin Kalinsky, Melissa K. Accordino, Codruta Chiuzan, Prabhjot S. Mundi, Elizabeth Sakach, Claire Sathe, Heejoon Ahn, Meghna S. Trivedi, Yelena Novik, Amy Tiersten, George Raptis, Lea N. Baer, Sun Y. Oh, Amelia B. Zelnak, Kari B. Wisinski, Eleni Andreopoulou, William J. Gradishar, Erica Stringer-Reasor, Sonya A. Reid, Anne O'Dea, Ruth O'Regan, Katherine D. Crew, Dawn L. Hershman
Publikováno v:
Journal of Clinical Oncology.
PURPOSE Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) improves progression-free survival (PFS) and overall survival (OS) in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–)
Autor:
Aditya, Bardia, Sara A, Hurvitz, Sara M, Tolaney, Delphine, Loirat, Kevin, Punie, Mafalda, Oliveira, Adam, Brufsky, Sagar D, Sardesai, Kevin, Kalinsky, Amelia B, Zelnak, Robert, Weaver, Tiffany, Traina, Florence, Dalenc, Philippe, Aftimos, Filipa, Lynce, Sami, Diab, Javier, Cortés, Joyce, O'Shaughnessy, Véronique, Diéras, Cristiano, Ferrario, Peter, Schmid, Lisa A, Carey, Luca, Gianni, Martine J, Piccart, Sibylle, Loibl, David M, Goldenberg, Quan, Hong, Martin S, Olivo, Loretta M, Itri, Hope S, Rugo, Amelia, Zelnak
Publikováno v:
The New England journal of medicine. 384(16)
Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in the major
Autor:
Amelia B, Zelnak, Kari B, Wisinski
Publikováno v:
Cancer. 121(1)
The successful development of therapies targeting the human epidermal growth factor receptor 2 (HER2) has altered the natural progression of disease among patients with HER2-positive metastatic breast cancer. The monoclonal antibody trastuzumab was t
Autor:
Amelia B, Zelnak, Ruth M, O'Regan
Publikováno v:
Oncology (Williston Park, N.Y.). 27(3)
The use of gene expression profiling has impacted our understanding of breast cancer biology and increasingly has played a role in guiding clinical decisions. We have used hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) stat
Autor:
Amelia B, Zelnak, Ruth, O'Regan
Publikováno v:
Cancer treatment and research. 141
Autor:
Amelia B, Zelnak
Publikováno v:
Methods in molecular medicine. 137
The microtubule-targeting agents have made significant contributions to cancer therapy over the past 50 years. The vinca alkaloids and taxanes have been used to treat a broad range of malignancies, including leukemias and lymphomas and many types of